US OptionsDetailed Quotes

XBI250425P72500

Watchlist

0.05
0.000.00%

15min DelayClose Apr 25 16:00 ET

0.00High0.00Low

SPDR S&P Biotech ETF Stock Discussion

amily

Mar 26 21:49

$Recursion Pharmaceuticals (RXRX.US)$ follow $SPDR S&P Biotech ETF (XBI.US)$

iamiam

Mar 19 20:09

Update, 19 Mar

A big day today, J Powow speaks, and the dots get plotted 😆
I will start with QQQ/ND and VIX, and then I will move to individual stocks. I don't own these and don't necessarily recommend buying them. I use them as sentiment and market bias/direction indicators.
I will be upfront and say my bias is up. How high doesn't really matter to me. I don't own the MAG 7. I just want to see willing buyers. I'm not nieve and am hedged for downside. but I have been buying a lot of individual ...

+33

FOMC holds rates amid heightened uncertainty: Where will US stocks head next?

MyTradeHunter

Mar 19 00:19

Issue #203 - Synthetic Stock on XBI (18.3.25)

Options Trading Newsletter Issue #203 from Substack.
SYNTHETIC Stock ON XBI
The SPDR S&P Biotech ETF (XBI) is an equal-weighted ETF that tracks the S&P Biotechnology Select Industry Index. Unlike market-cap-weighted ETFs, XBI gives equal exposure to small, mid, and large biotech stocks. This makes it more volatile compared to other biotech ETFs like IBB, which is more weighted toward large-cap biotech firms.
XBI Price Action Analysis
– XBI has been on...

74425369

Mar 10 19:40

INSIDER BUY ALERT: JANX

What happened: In recent weeks, $Janux Therapeutics (JANX.US)$ has seen significant insider buying, notably from RA Capital Management, which acquired shares worth approximately $25.3M.
Big picture: Janux's stock has been volatile, trading near its 52-week low. Investor sentiment remains cautious amidst broader biotech sector challenges.
Key Developments:
📊 Positive Clinical Data: JANX007 showed impressive results in Phase 1 trials for metastatic castration-resistant prost...

MyTradeHunter

Mar 6 23:02

Issue #201 - Recycling IWM Strangle

from Substack MyTradeHunter Newsletter
Market Scorecard
Market is weak with NQ dropping more than 7% and ES more by 5%. On contrast HSI has remained strong in anticipation of positive news flows coming out from the CCP Meetings in China, ongoing.
Trade Scorecard
IBIT Call Ratio (Update)
IBIT has hit roller coaster with selloff to a low of $46.07. Price has since recovered to $51.44.
We closed the short call 57C on 27 February when IBIT hit lows of $46.90 for $0...

Kim10

Jan 9 06:20

$SPDR S&P Biotech ETF (XBI.US)$ big bearish flow coming in looking like a hedge. Potential put play, small size.

topcing

Nov 5, 2024 11:29

$SPDR S&P Biotech ETF (XBI.US)$ yea

股勇者

Oct 25, 2024 23:17

$SPDR S&P Biotech ETF (XBI.US)$ 100 month end? ok?

Bellaah

Sep 12, 2024 00:10

$SPDR S&P Biotech ETF (XBI.US)$ 95

Moomoo Learn

Sep 6, 2024 16:05

Columns Navigating the wave of lower interest rates

Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...